 4D pharma PLC AIM:DDD, NASDAQ:LBPS said it is to present microbiome analyses from its phase II clinical trial of its drug Blautix, revealing its impact on the two major forms of irritable bowel syndrome IBS-C and IBS-D. The results, to be presented in an e-poster at the Gastro 2021 conference starting December 11, chat changes in gut microbiome structure following administration of the 4D live biotherapeutic. 